Share on StockTwits
 

Investment analysts at Deutsche Bank increased their price objective on shares of CSL Limited (ASX:CSL) from $71.00 to $78.00 in a note issued to investors on Thursday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock.

CSL has been the subject of a number of other recent research reports. Analysts at Credit Suisse reiterated an “outperform” rating on shares of CSL Limited in a research note to investors on Thursday, January 16th. They now have a $74.55 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of CSL Limited in a research note to investors on Sunday, November 24th. They now have a $70.70 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of A$73.76 ($64.70).

Shares of CSL Limited (ASX:CSL) traded down 0.01% on Thursday, hitting A$70.130. 100 shares of the company’s stock traded hands. CSL Limited has a one year low of A$52.250 and a one year high of A$71.130. The stock’s 50-day moving average is A$68.16 and its 200-day moving average is A$66.86. The company has a market cap of A$34.178 billion and a P/E ratio of 28.85.

CSL Limited is an Australia-based company. The Company is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.